泰索帝联合顺铂治疗蒽环类耐药性晚期乳腺癌28例

Docetaxel Combined with Cisplatin in the Treatment of Anthracycline-Resistent Advanced Breast Cancer

目的 观察泰索帝联合顺铂治疗蒽环类耐药性晚期转移性乳腺癌28例的疗效与毒副反应。方法 泰索帝75 mg/m^2,静滴,d1;顺铂75 mg/m^2,静滴,d2-4,同时给与水化、利尿、止吐以及抗过敏预处理等治疗,21 d为1周期。中位化疗周期数为3个（2-5个）周期。结果 28例均可评价疗效。完全缓解（CR）2例（7.1%）,部分缓解（PR）13例（46.4%）,稳定（SD）6例（21.4%）,进展（PD）7例（25%）,总有效（CR＋PR）15例（53.6%）,中位肿瘤进展时间（TTP）5.6个月,1年生存率63.7%。主要毒副反应为骨髓抑制、恶心、呕吐。结论 泰索帝和顺铂联合治疗蒽环类耐药的晚期转移性乳腺癌疗效较好,毒副反应轻,耐受性较好,是蒽环类耐药性乳腺癌的有效治疗方案。

Objective To evaluate the efficacy and toxicity of combined chemotherapy of docetaxel （DOC） combined with cisplatin （DDP） for 28 patients with anthracyciine-resistant advanced breast cancer （ ABC）. Methods Docetaxel was administered at a dose of 75 mg/m2 on d1 every three weeks. Then, cispiatin of 75 mg/m2 on d2-4. Meanwhile, hydrathon, lasix and active antivomitthy drug were given. The median number of cycles was 3 （range ：2 -5 cycles）. Results The overall combined chemotherapy response rate was 53.6% . With a medion time to progression of 5.6 months. One-year survival rate was 63.7%. The main side effects were nausea, vomiting and hematologic toxicities. Conclusions Docetaxel and cispiatin combination is active in the treatment of patient with anthracycine-resisitant advanced breast cancer the toxichty was acceptable and it may be a therapeutic alternative after anthracyciine ragemen fails.